background image
Proven Medicines. Improved Delivery.
Wilmington Pharma Zydis

At Wilmington Pharmaceuticals, we develop and out-license patient-friendly, fast-dissolving formulations for established medicines. We achieve FDA approval and rapid commercialization for our licensing partners, minimizing regulatory risk while maximizing economic opportunity. Our points of differentiation provide you with an ideal development partner.

  • We exclusively license Catalent Pharma Solutions' Zydis® technology for use in Metozolv ODT (metoclopramide) and our current development products in pain and the central nervous system. Zydis® is the gold standard of fast-dissolve formulations, providing improved patient comfort and compliance and enhancing physician results
  • Our proven 505(b)(2) expertise leads to low-risk, rapid approvals of valuable NDA products
  • Our marketing license partners achieve a reliably high return on investment, while delivering important medical advantages to physicians and patients

Reference: 1. Schwartz JI, Yeh KC, Berger ML, et al. Novel oral medication delivery system for famotidine. J Clin Pharmacol. 1995;35:362-367.

Zydis® is a registered trademark of Catalent Pharma Solutions.

75% of patients expressed a preference for
the fast-dissolve formulation compared with a tablet.1
Click here to learn more.

dotted line

Value“Numerous surveys have shown that a majority of patients would prefer to receive their medicine in a fast-dissolve format. Addressing this significant unmet patient need can translate into meaningful market shares and high returns on investment.”Eugene T. Haley, Chief Executive Officer